Kornimate/medical-research-clean huggingface dataset:
high tone power therapy versus transcutanuoselectrical nerve stimulation on polyneuropathic pain in diabetic patients

Conditions: Diabete Mellitus

Summary: the results of this study may provide an easy non pharmacological modality for dealing with diabetic polyneuropathic pain. also, the outcome of this study will guide physiotherapists to develop a new noninvasive treatment modality that may improve patient symptoms and promotes their social participation , this in turn may add to clinical role played by therapists in management of diabetic polyneuropathy. in addition, increased knowledge of the influence of high tone power therapy on neuropathic pain

this study will be carried out on sixty diabetic male patients with polyneuropathy with ages 50-60 years . patient will be randomly assigned to two grouos. group a will include 30 type 2 diabetic patients with diabetic polyneuropathy. theses patients will receive high tone power therapy with frequencies continuously will be scanned from 4096 hz to 31768 hz, allowing for a much higher power of up to 5000 mw to be introduced for 3 times per week, for 3 months for 30 minutes every session. group b : this group will include 30 type 2 diabetic patients with diabetic neuropathy. these patients will receive tens with applied frequencies range from 2 to 120 hz. for 3 times per week for 30 minutes every session during 3 months of intervention.

Eligibility criteria:
inclusion criteria: * the patient selection will be according to the following criteria: 1. sixty male patients are diagnosed with diabetic polyneuropathy their ages will be ranged from 50-60 years old. 2. all patients are ambulant independently. 3. all patients are under full medical control 4. hba1c is ranged from 6.5 : 7 %. 5. patients has diabetes more than 10 years. exclusion criteria: * the participants will be excluded if they meet one of the following criteria: 1. psychiatric disorders or seizures. 2. visual and auditory impairment or tremors influencing balance. 3. other neuromuscular disorders. 4. foot deformities and ulcers. 5. lower limb operations. 6. feverish systemic infection 7. cardiac pacemaker.
quality of life and personality traits in patients with type 1 diabetes

Conditions: Type 1 Diabetes; Quality of Life

Summary: the aims of this study are to examine the differences in the quality of life among individuals with type 1 diabetes and individuals without chronic diseases, differences in the quality of life among men and women with type 1 diabetes and the differences in the quality of life among individuals with good and poor glycaemic control. the relationship between personality traits and the management of disease in patients with type 1 diabetes will also be examined.

diabetes affects the daily life of patients, chronic diseases have a major impact on the quality of life of individuals. chronic illness affects family life of an individual, his professional life, as well as leisure activities, chronic illness can also increase worries, fears, feelings of sadness and helplessness. past studies examining the quality of life construct in patients with type 1 diabetes (t1d) showed that patients achieved lower levels of life quality, compared to individuals without t1d. studies show that women with t1d achieve lower scores on the quality of life scales than men with t1d and differences in gender are already present in adolescence. patients with poor glycaemic control achieve lower results on the quality of life scales, the effect of hemoglobin on the quality of life is direct, as well as indirect. the studies in which they examined the attitudes of personality traits with diabetes management show that two personality traits are associated with the management of the disease, the successful management of the disease is primarily associated with the conscientiousness. concerning the effect of neuroticism on the management of the disease, research results are contradictory.

Eligibility criteria:
inclusion criteria: * age between 18 and 35 * diagnosed with type 1 diabetes for at least one year (for the t1d group) * willing to participate in study exclusion criteria: -

Keywords: type 1 diabetes quality of life personality traits young adults
study of cx-4945 in patients with relapsed or refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: this phase 1 study of oral cx-4945 is designed to test the safety, tolerability, and highest safe dose level of this ck2 inhibitor in patients with relapsed or refractory multiple myeloma.

elevated ck2 activity has been associated with malignant transformation and aggressive tumor growth. over expression of ck2 has been documented in multiple types of cancers, including multiple myeloma, and inhibition of ck2 represents a potential therapeutic strategy to target a specific molecular defect perpetuating many cancers. cx-4945 has demonstrated potent inhibition of ck2 enzymatic activity. this study will evaluate the safety, pharmacokinetics, and pharmacodynamic effects of cx-4945 when administered to patients with multiple myeloma.

Eligibility criteria:
inclusion criteria: * males or females at least 18 years of age * confirmed relapsed or refractory multiple myeloma after at least two prior lines of therapy. * measureable disease. * karnofsky performance status at least 60% * adequate liver and renal function and hematology laboratory values * female patients of child-bearing potential must have a negative pregnancy test. * signed informed consent. exclusion criteria: * treatment with systemic cancer therapy within 21 days before screening. * major surgery within 4 weeks or minor surgery within 2 weeks of the start of study drug. * grade 3 sensory neuropathy or motor neuropathy with pain * concurrent severe or uncontrolled medical disease. * active systemic fungal, bacterial, and/or viral infection. * difficulty with swallowing, or an active malabsorption syndrome. * gastrointestinal diseases including crohn's disease or hemorrhagic coloproctitis. * history of gastric or small bowel surgery. * pregnant or nursing females.

Keywords: multiple myeloma plasmacytoma
the effect of virtual reality glasses used before cesarean section

Conditions: Anxiety

Summary: the aim of this study is to determine the effect of virtual reality glasses used before cesarean section on surgical fear and anxiety

hypotheses 01; there was no difference between the surgical fear and anxiety score of the virtual reality glasses group and the control group. the study will be carried out in two different groups. the practice will start with meeting the women whom will go to cesarean section in the hospital. after the women are evaluated in terms of eligibility criteria for the research, the women who are eligible will be informed about the research and written informed consent will be obtained from the women who accept. the random distribution of women to the study groups will be carried out using the block randomization method. the following applications will be made to the groups. virtual reality glasses group; the intervention will be given glasses before the surgery and will be shown a video (30 minutes) of the 9-month fetal development process. among the women who were admitted for a planned caesarean section, those who met the criteria would first be given the informed consent form and a data collection form including sociodemographic characteristics, surgical fear scale, spielberg state-trait anxiety scale, and then randomization would be applied. control group; the first surgical fear scale, anxiety scores will be recorded. after cesarean section anxiety scores will be recorded.

Eligibility criteria:
inclusion criteria: * will undergo a cesarean section for the first time, * are over the age of 18, * have no diagnosed mental illness, * have no diagnosed physical illness in themselves or their baby, * volunteer to participate in the study exclusion criteria: * have previously undergone a cesarean section, * are under the age of 18, * have a diagnosed mental illness, * have a diagnosed physical illness in themselves or their baby, do not volunteer to participate in the study. -
photobiomodulation, cryotherapy combined with compression, and massage for recovery

Conditions: Laser; Muscle; Fatigue, Heart; Muscle Damage

Summary: skeletal muscle fatigue is an inevitable phenomenon in the training and competition routine for many crossfit athletes, which can impair their physical performance and predispose them to musculoskeletal injuries. thus, strategies and/or therapies that minimize fatigue and accelerate muscle recovery are extremely relevant for everyone involved with sport. the aim of the present study is to investigate and compare the effects of photobiomodulation, cryotherapy combined with compression, and massage as isolated therapies for muscle recovery after a protocol of induced muscle damage and fatigue in crossfit athletes. this is a randomized, double-blind, crossover, sham-controlled clinical trial. will be recruited 60 male participants, adults, aged between 18 and 40 years, crossfit practitioners. they will be randomly allocated into 3 groups of 20 participants per therapy, each crossed between effective and sham every 15 days. the primary outcome will be muscle performance in functional test (free squat) and knee extensor torque in maximal voluntary isometric contraction (mvic). secondary outcomes will be evaluated by the levels of muscle damage via creatine phosphokinase (cpk) and inflammatory process via blood c-reactive protein (crp); and delayed onset muscle pain via numerical verbal scale (0-10). all outcomes will be evaluated at baseline, 24h and 48h after induction of muscle damage and fatigue. data will be analyzed and compared intra and inter groups with a significance level of 5%.

this is a randomized, double-blind, crossover, controlled clinical trial of sham therapy.

Eligibility criteria:
inclusion criteria: * male participants; * adults; aged between 18 and 40 years; * body mass index (bmi) between 18 and 30 kg/m2; * crossfit practitioners of the scale, amateur, rx and elite categories; * training at least 5 days a week. exclusion criteria: * orthopedic injuries in the lower limbs (2 months) or during the development of the study will be excluded; * participants with less than 5 training sessions per week; * participants making regular use of pharmacological agents and/or ergogenic supplements; * participants who regularly use alcohol and/or tobacco; * participants with skin lesions (open wounds) on the lower limbs.

Keywords: photobiomodulation crossfit muscle damage
ic plus low-dose radiation plus cadonilimab in lanpc

Conditions: Nasopharyngeal Carcinoma; Immune Checkpoint Inhibitor; Radiotherapy; Chemotherapy

Summary: this is a multi-center, open-label, randomized controlled phase iii clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (npc) patients. the purpose of this study is to evaluate the efficacy of induction chemotherapy (ic) combined with low-dose radiation and immune checkpoint inhibitor (ici) followed by concurrent chemoradiotherapy (ccrt) versus ic+ccrt, and compare the treatment-related adverse events and quality of life in two groups.


Eligibility criteria:
inclusion criteria: * newly histologic diagnosis of nasopharyngeal non-keratinizing carcinoma (who ii/iii); * all genders, range from 18-70 years old; * ecog score 0-1; * clinical stage t4n1m0 and t1-4n2-3m0 (ajcc/uicc 8th); * not received radiotherapy, chemotherapy and other anti-tumor treatment (including immunotherapy); * no contraindications to chemotherapy, radiotherapy or immunotherapy; * adequate organ function: white blood cell count ≥ 4×109/l, neutrophile granulocyte count ≥ 1.5×109/l, hemoglobin ≥ 9g/l, platelet count ≥ 100×109/l; alanine aminotransferase or aspartate aminotransferase \< 2.5×upper limit of normal; blood urea nitrogen or creatinine ≤ 1.5×upper limit of normal or endogenous creatinine clearance ≥ 60ml/min (cockcroft-gault formula); * sign the consent form. exclusion criteria: * distant metastases; * keratinized squamous cell carcinoma or basal cell like squamous cell carcinoma; * have or are suffering from other malignant tumors; * participating in other clinical trials; * pregnancy or lactation; * have uncontrolled cardiovascular disease; * severe complication, eg, uncontrolled hypertension; * mental disorder; * drug or alcohol addition; * do not have full capacity for civil acts.
quantitation of endothelial progenitor cells as markers of tumor angiogenesis in breast cancer

Conditions: Breast Cancer Stage IV; Breast Cancer Stage I; Breast Cancer Stage II

Summary: we propose to quantitate endothelial progenitor cells (epcs) in early and advanced breast cancer patients. peripheral blood will be drawn from the eligible patients. different type of epcs will be isolated from the blood and quantitated.

accumulating evidence emphasizes the emerging role of circulating endothelial cells (cecs) and endothelial progenitor cells (epcs) in tumor angiogenesis as surrogate markers and in the efficacy of anti-angiogenic therapies in breast cancer (22-27). furstenberger et al. (22) reported that cecs were significantly elevated in breast cancer patients and decreased during chemotherapy (anthracycline and/or taxane based). however, epcs (cd34+/vegfr-2+) as well as their progenitor cell population cd133+/cd34+ and the population of cd34+ stem cells increased together with vegf, erythropoietin and angiopoietin-2 levels. their data suggest that chemotherapy reduces mature cecs, while mobilizing the epc population. using real-time pcr and flow cytometry, they also showed that cd146, an endothelial cell specific antigen, was significantly increased in newly diagnosed breast cancer patients compared to healthy controls (23). other studies also reported increased circulating epcs in breast cancer patients in addition to cecs (24,25). in another study, circulating epcs were not increased in cancer patients despite the high plasma vegf levels (26). another interesting aspect is that mancuso et al (27) showed that cec kinetics correlate with progression-free and overall survival but not circulating progenitor cells in metastatic breast cancer.

Eligibility criteria:
inclusion criteria: * diagnosis of metastatic breast cancer(stage iv), or women with a history of stage i or ii breast cancer disease who are currently disease free women greater than or equal to 18 years of age ability to understand and the willingness to sign an informed consent exclusion criteria: * chemotherapy, radiation, or surgery within the past 4 weeks.

Keywords: breast cancer
egfr-tki resistance profile in chinese patients with advanced egfrm+ nsclc

Conditions: Nonsmall Cell Lung Cancer

Summary: a prospective multi-center study to investigate the egfr-tki resistance profile in chinese patients with advanced egfrm+ nsclc

patients with egfr mutation and presented secondary resistance to prior first-generation egfr-tki should have received biopsy of at least on progressed lesions and are able to provide tissues for pathological examination and ngs testing.all enrolled patients will be followed up to clinical outcome (treatments, tumor response, survival, etc).

Eligibility criteria:
inclusion criteria: * provision of informed consent prior to any study specific procedures. * male or female patients aged 18 years and older. * histological confirmation of stage iiib/iv nsclc. * documented egfr mutation positive . * who performance status 0, 1 or 2 exclusion criteria: * any other significant clinical disorder or laboratory finding that made it undesirable for the patient to participate in the study. * previous (within 6 months) or current treatment with azd9291.
effectiveness of oral hyaluronic acid (a+ ha(tm), top pharm.) in knee osteoarthritis: clinical trial

Conditions: Knee Osteoarthritis

Summary: this is a double-blinded, placebo-controlled, randomized trial to assess the efficacy of oral solution of hyaluronic acid mixture (a+ ha(tm)). during 8 weeks treatment period, there were three follow-up visits requested (week 2, week 4 and week 8).

subjects were initially screened at the randomization/baseline visit (week 0). eligible subjects were randomized at the same visit into treatment period, and received the assigned treatment in a double-blind fashion for 8 weeks. efficacy was measured by the several questionnaire including knee injury and osteoarthritis (koos), the short form-36 (sf-36) and pittsburgh sleep quality index (cpsqi) for each visit. incidences of adverse events (aes) were monitored for each subject once the subject had received 1 dose of study medication; the incidence of serious aes (saes) were monitored for each subject once the subject had signed the informed consent through to the end-of-study or et visit. vital signs were measured at baseline and end-of-study or et visit.

Eligibility criteria:
inclusion criteria: 1. age \>= 40 years old 2. male or female 3. with osteoarthritis of the knee based on the definition of ahlback 1968 and with significant symptoms within 30 days before enrollment. 4. no limitation for use of concomitant medication exclusion criteria: 1. use of glucosamine within 1 month before enrollment 2. osteoarthritis of the knee due to exercise or occupational injury 3. allergy with oral hyaluronic acid 4. bilateral total knee replacement 5. pregnant 6. need use wheelchairs 7. bmi≥40 8. with at least one condition: known other causes of arthritis (infectious arthritis, rheumatoid arthritis, connective tissue disease, gout, pseudogout, or psoriatic arthritis), bony or soft tissue malignancy or skin lesions or peripheral neuropathy involving the lower extremities, cardiopulmonary disease which limits walking more than knee pain. knee instability defined as report of knee bucking or locking within the past month of the study knee, major neurologic deficit that affects gait, psychiatric illness that limits informed consent, and parkinsonism. 9. cancer
retrospective data collection for a correlation study between gastric cancer and clinical and laboratory variables

Conditions: Gastric Cancer Patient

Summary: this is an observational, retrospective, case-control, single-center, national study that involves the collection of anamnestic, clinical and therapeutic data of patients diagnosed with gastric cancer by histological examination at the pathological anatomy unit (prof. d'errico) in the period 2016-2020.

the corresponding medical records will be analyzed to derive information on the socio-demographic characteristics and risk factors of the included subjects. each case will be paired with two controls chosen from patients who have performed a gastric biopsy with relative histological examination during an endoscopic examination carried out at the irccs azienda ospedaliero-universitaria of bologna.

Eligibility criteria:
inclusion criteria cases: * età \> 18 anni. * diagnosi istologica di carcinoma gastrico * ottenimento del consenso informato. inclusion criteria controls: * età \> 18 anni. * esecuzione di indagine endoscopica gastrica con relativo esame istologico (mucosa sana, gastrite acuta, gastrite cronica con o senza infezione da helicobacter pylori, metaplasia intestinale) * ottenimento del consenso informato. exclusion criteria: * none

Keywords: gastric cancer, helicobacter pylori
oral stent device for radiation treatments of oral cancers

Conditions: Tongue Tumor; Tongue Cancer

Summary: the purpose of this study is to examine that ability of the experimental oral stent device to reduce the volume of mandible receiving \>55 gy by 50%during radiation treatment as assessed duri radiation treatment planning. patients will have ct scans at three time-points during their standard of care radiation treatment. during these visits patients will receive scans via ct or cone beam ct scan, with both the standard and experimental oral stent devices. during radiation treatment patients will receive the standard oral stent device.


Eligibility criteria:
inclusion criteria: * ≥18 year old at the time of informed consent * ability to provide written informed consent and hipaa authorization * accepted for curative radiation treatment of a tongue tumor, either intact or postoperatively * signed consent to study participation * no history of bleeding disorder * platelets within normal limits (150-450 k/cumm) exclusion criteria: * history of bleeding disorder * history of allergy to dental grade material

Keywords: tongue tumor tongue cancer oral cancer
determination of the validity of a questionnaire to assess the visual function of preverbal children with operable bilateral ocular pathologies

Conditions: Eye Diseases; Vision Disorders

Summary: in some symmetrical pediatric ocular pathologies, the treatment is surgical with usually satisfactory postoperative results in visual terms. however, it is often difficult to choose the right moment to operate. the main difficulty is that the child's vision is unknown since the child is still in a preverbal age. the investigators have developed a questionnaire with the aim of quantifying the child's vision so that the decision is most justified. the items of this questionnaire were established based on the literature and were submitted to a panel of experts in ophthalmo-pediatrics. the objective of this study is to determine the internal validity and as far as possible (since there is no equivalent tool) the external validity of the questionnaire developed.


Eligibility criteria:
inclusion criteria: common to the three groups: * patient aged 0 to 36 months * diagnosis of known ocular pathology for patients targeted by the questionnaire: - patient with operable bilateral ocular pathology for negative controls: - patient without ocular pathology inducing a decrease in vision for positive controls: * patient with inoperable bilateral ocular pathology * patient without light perception exclusion criteria: * patient with unilateral ocular pathology * verbal patients (able to express themselves through speech)

Keywords: eye diseases vision disorders questionnaire design children infant
adipokines effect in myometrial contractility

Conditions: Myometrium; Contractility; GDM; Obesity

Summary: investigate the effect of two adipokines which are adiponectin and tnfa on the force of myometrial contractility in diabetic, non-obese pregnant women and obese, non-diabetic term pregnant women at the time of scheduled cesarean delivery


Eligibility criteria:
inclusion criteria: * pregnant patients scheduled for a cs at 37-41 weeks of gestation at m health birth place * participants age ≥18. * full informed consent able to be provided by the participant. exclusion criteria: * patients undergoing general anesthesia for their cs. * pre-gestational dm, and dm diagnosed \<24 weeks gestation. * patients unable to consent for themselves * multiple gestation